Quillivant Suspension, Extended Release
Product Images NDC 24478-322

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Quillivant (NDC 24478-322). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nextwave Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Quillivant Xr 1

Chemical structure of Quillivant XR active ingredient showing its molecular components and hydrochloride form (HCl). The diagram includes distinct chemical groups including a methoxy group, phenyl ring, and cyclohexane ring attached to a nitrogen atom.*

FDA Label Image

Figure M (Quillivant Xr 10)

Two black-and-white instructional diagrams related to product assembly and use. Figure E depicts a bottle adapter isolated on a white background. Figure F shows a hand gripping a bottle with an arrow pointing downward, indicating a pressing or twisting action on the bottle cap or adapter.*

FDA Label Image

Figure N (Quillivant Xr 11)

An instructional line drawing labeled Figure G demonstrating a hand holding a bottle of Quillivant XR with the bottle adapter fully inserted, illustrating proper assembly for use.*

FDA Label Image

Prinicpal Display Panelndc 24478-321-02quillivant Xr® Methylphenidate Hci For Extended-release Oral Suspension300 mg/ 60 mL Total Volume(when Reconstituted With 53 mL Of Water)25 mg/5 mL(5 mg/ml) When Reconstitutedrx Only (Quillivant Xr 12)

An illustration labeled 'Figure H' showing a syringe with a graduated barrel displaying measurement markings from 1 mL up to 12 mL. The image includes a magnified inset highlighting finer gradations between 1 mL to 4 mL. The syringe has a plunger at the base. This diagram likely depicts syringe volume measurement details.*

FDA Label Image

Prinicpal Display Panelndc 24478-322-04quillivant Xr® Methylphenidate Hci For Extended-release Oral Suspension600 mg/ 120 mL Total Volume(when Reconstituted With 105 mL Of Water)25 mg/5 mL(5 mg/ml) When Reconstitutedrx Only (Quillivant Xr 13)

Instructional diagram showing how to hold and press the bottle of Quillivant XR oral suspension. One hand grips the bottle while the other hand presses down on the top to activate or release the medication.*

FDA Label Image

Prinicpal Display Panelndc 24478-323-05quillivant Xr® Methylphenidate Hci For Extended-release Oral Suspension750 mg/ 150 mL Total Volume(when Reconstituted With 131 mL Of Water)25 mg/5 mL(5 mg/ml) When Reconstitutedrx Only (Quillivant Xr 14)

An instructional illustration labeled Figure J showing hands holding a syringe-like device, with one hand pressing down on the plunger and an arrow indicating a downward motion. This likely demonstrates how to use or prepare the device for administration.*

FDA Label Image

Prinicpal Display Panelndc 24478-324-06quillivant Xr® Methylphenidate Hci For Extended-release Oral Suspension900 mg/ 180 mL Total Volume(when Reconstituted With 158 mL Of Water)25 mg/5 mL(5 mg/ml) When Reconstitutedrx Only (Quillivant Xr 15)

An instructional illustration labeled as Figure K showing a hand holding a dosing syringe with a bottle on top, demonstrating how to measure the liquid medication to the white end of the plunger.*

FDA Label Image

Quillivant Xr 16

An instructional illustration showing a child receiving an oral dose of medication via an oral syringe positioned in the child's mouth, demonstrating how to administer liquid medication.*

FDA Label Image

Quillivant Xr 17

An instructional illustration showing a hand twisting a bottle cap to open or close it, indicated by an arrow depicting the direction of rotation. The drawing style is simple and clear to guide proper bottle cap handling.*

FDA Label Image

Quillivant Xr 18

An instructional illustration showing hands preparing a liquid medication with a syringe. The left panel depicts drawing liquid from a cup by pulling the syringe plunger upward. The right panel shows administering the liquid by pressing the plunger downward.*

FDA Label Image

Quillivant Xr 19

FDA Label Image

Quillivant Xr 2

A line graph comparing the mean d-Methylphenidate plasma concentration (ng/mL) over time (hours) between Quillivant 60 mg and Methylphenidate IR Oral Solution dosed as 2x30 mg every 6 hours. The graph shows plasma concentration on the vertical axis and time up to 40 hours on the horizontal axis, illustrating the pharmacokinetic profile of both formulations.*

FDA Label Image

Quillivant Xr 20

The image shows the packaging label for Quillivant XR 300 mg/60 mL extended-release oral suspension. It contains methylphenidate HCl at 25 mg/5 mL concentration when reconstituted. The label instructs to shake well before use and to reconstitute with 53 mL of water prior to dispensing. It includes warnings, pharmacist instructions, and the labelers NextWave Pharmaceuticals, Inc and Tris Pharma details. The label is designed for a 60 mL bottle volume.*

FDA Label Image

Quillivant Xr 21

Packaging label for Quillivant XR methylphenidate HCl extended-release oral suspension, 600 mg/120 mL total volume (25 mg/5 mL when reconstituted). The label includes instructions to shake well for at least 10 seconds before use and to reconstitute with 105 mL of water prior to dispensing. Distributed by NextWave Pharmaceuticals, Inc and manufactured by Tris Pharma, Inc. The label also notes to keep out of reach of children and to dispense the enclosed medication guide to each patient.*

FDA Label Image

Quillivant Xr 22

Packaging label for Quillivant XR 750 mg/150 mL extended-release oral suspension of methylphenidate HCl. The label instructs reconstitution with 131 mL of water to yield 25 mg/5 mL concentration and includes directions to shake well before use. The labeler is NextWave Pharmaceuticals, Inc. Instructions for pharmacists and warnings such as keeping out of reach of children are also displayed. The label features logos for Tris Pharma and LiquiXR.*

FDA Label Image

Quillivant Xr 23

Packaging label for Quillivant XR methylphenidate HCl extended-release oral suspension, 900 mg/180 mL total volume (25 mg/5 mL or 5 mg/mL when reconstituted). Label includes instructions to shake well for at least 10 seconds before use and reconstitution instructions with 158 mL of water. Distributed by NextWave Pharmaceuticals, Inc, with additional labeling from Tris Pharma and LiquiXR.*

FDA Label Image

Quillivant Xr 3

Line graph showing mean combined SKAMP scores with standard error bars over a 12-hour period for Quillivant XR versus placebo. The x-axis represents timepoints in hours, while the y-axis shows mean SKAMP scores. Quillivant XR group scores decrease and remain lower compared to the placebo group, which shows higher and more variable scores over time.*

FDA Label Image

Quillivant Xr 4

FDA Label Image

Quillivant Xr 5

FDA Label Image

Quillivant Xr 6

Illustration labeled Figure A showing components of a product package. The image includes a box, a bottle, and a unit dosing dispenser (a syringe-like device) displayed separately. The illustration likely depicts the parts included for dispensing the medication.*

FDA Label Image

Quillivant Xr 7

An illustration titled 'Figure B' depicting a bottle with a cap containing liquid, labeled simply as 'Liquid.' The diagram visually identifies the liquid content inside the bottle.*

FDA Label Image

Quillivant Xr 8

An instructional illustration labeled 'Figure C' demonstrating how to shake a bottle well before use. The image shows a hand holding a bottle with arrows indicating an up-and-down shaking motion.*

FDA Label Image

Quillivant Xr 9

Illustration labeled Figure D showing a hand holding and placing a bottle adapter onto a bottle, demonstrating the assembly process for the Quillivant XR suspension bottle.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.